Abeona therapeutics announces regulatory update on biologics license application (bla) for eb-101

Cleveland, june 09, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced that it received feedback from the u.s. food and drug administration (fda) on june 8, 2023, in which the company gained the agency's alignment on the data required to establish retroviral vector (rvv) comparability, a critical chemistry, manufacturing and controls (cmc) component for the eb-101 biologics license application (bla).
ABEO Ratings Summary
ABEO Quant Ranking